Testing for BRAF V600 mutations in cell-free DNA from plasma using the PCR-based IdyllaTM BRAF Mutation Test was feasible and concordant with standard tests of archival tumor biopsy samples and had a ...
--Roche Group’s Personalized Healthcare Approach Demonstrated Through Vemurafenib and its Investigational Companion Diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test -- CHICAGO--(BUSINESS WIRE)-- ...
Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according to ...
Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results